celecoxib has been researched along with Amyotrophic Lateral Sclerosis in 9 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS)." | 9.12 | Trial of celecoxib in amyotrophic lateral sclerosis. ( Andreasson, KI; Cudkowicz, ME; Drachman, DB; Rothstein, JD; Schoenfeld, DA; Shefner, JM; Zhang, H, 2006) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 7.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| "To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS)." | 5.12 | Trial of celecoxib in amyotrophic lateral sclerosis. ( Andreasson, KI; Cudkowicz, ME; Drachman, DB; Rothstein, JD; Schoenfeld, DA; Shefner, JM; Zhang, H, 2006) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 3.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a rare neurodegenerative disease." | 2.45 | Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. ( Benatar, M; Kurent, J; Moore, DH, 2009) |
| "Celecoxib treatment significantly delayed the onset of weakness and weight loss and prolonged survival by 25%." | 1.31 | Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. ( Almer, G; Drachman, DB; Dykes-Hoberg, M; Frank, K; Przedborski, S; Rothstein, JD; Teismann, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Salomon-Zimri, S | 1 |
| Pushett, A | 2 |
| Russek-Blum, N | 2 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 4 |
| Drory, VE | 2 |
| Goldshtein, H | 1 |
| Muhire, A | 1 |
| Petel Légaré, V | 1 |
| Rotkopf, R | 1 |
| Peterson, RT | 1 |
| Armstrong, GAB | 1 |
| Xia, Q | 1 |
| Hu, Q | 1 |
| Wang, H | 1 |
| Yang, H | 1 |
| Gao, F | 1 |
| Ren, H | 1 |
| Chen, D | 1 |
| Fu, C | 1 |
| Zheng, L | 1 |
| Zhen, X | 1 |
| Ying, Z | 1 |
| Wang, G | 1 |
| Gordon, PH | 1 |
| Cheung, YK | 1 |
| Levin, B | 1 |
| Andrews, H | 1 |
| Doorish, C | 1 |
| Macarthur, RB | 1 |
| Montes, J | 1 |
| Bednarz, K | 1 |
| Florence, J | 1 |
| Rowin, J | 1 |
| Boylan, K | 1 |
| Mozaffar, T | 1 |
| Tandan, R | 1 |
| Mitsumoto, H | 1 |
| Kelvin, EA | 1 |
| Chapin, J | 1 |
| Bedlack, R | 1 |
| Rivner, M | 1 |
| McCluskey, LF | 1 |
| Pestronk, A | 1 |
| Graves, M | 1 |
| Sorenson, EJ | 1 |
| Barohn, RJ | 1 |
| Belsh, JM | 1 |
| Lou, JS | 1 |
| Levine, T | 1 |
| Saperstein, D | 1 |
| Miller, RG | 1 |
| Scelsa, SN | 1 |
| Benatar, M | 1 |
| Kurent, J | 1 |
| Moore, DH | 1 |
| Nefussy, B | 1 |
| Hirsch, J | 1 |
| Cudkowicz, ME | 3 |
| Drachman, DB | 2 |
| Frank, K | 1 |
| Dykes-Hoberg, M | 1 |
| Teismann, P | 1 |
| Almer, G | 1 |
| Przedborski, S | 1 |
| Rothstein, JD | 2 |
| Schoenfeld, DA | 1 |
| Zhang, H | 2 |
| Andreasson, KI | 1 |
| Schoenfeld, D | 1 |
| Jillapalli, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis[NCT02164253] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Treatment for familial amyotrophic lateral sclerosis/motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Creatine; Fructos | 2009 |
3 trials available for celecoxib and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Celecoxib; Creatine; Double-Blind Met | 2008 |
Trial of celecoxib in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dino | 2006 |
5 other studies available for celecoxib and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Celecoxib; Ciprofloxacin; Dis | 2020 |
Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia.
Topics: Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Celecoxib; Cell Death; Cell Line; Cyclooxygenase | 2015 |
Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Celecoxib; Disease Progression; Dyslipidemias; Female; Fructose | 2011 |
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2002 |
Revised statistical motor unit number estimation in the Celecoxib/ALS trial.
Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib | 2007 |